Matching articles for "ticagrelor"
Issue 1593 · March 9, 2020 Free
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors

Opioids delay gastric emptying and the absorption of many oral drugs, including the P2Y 12 inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) ,…

Med Lett Drugs Ther. 2020 Mar 9; 62(1593):40
Opioids delay gastric emptying and the absorption of many oral drugs, including the P2Y 12 inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) , which are commonly used for initial treatment of acute coronary syndrome (ACS). An article in our February 25, 2019 issue reviewed studies showing that coadministration of opioids delayed and decreased absorption of oral P2Y 12 inhibitors and increased platelet reactivity. Recently published clinical outcomes data may add to these concerns.
Issue 1566 · February 25, 2019
Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors

The FDA has required manufacturers of the oral P2Y 12 platelet inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) to warn in the product labels that…

Med Lett Drugs Ther. 2019 Feb 25; 61(1566):31-2
The FDA has required manufacturers of the oral P2Y 12 platelet inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) to warn in the product labels that the absorption of these drugs may be delayed or reduced when taken with an opioid agonist.
Issue 1480 · October 26, 2015
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI

The FDA has approved cangrelor ( Kengreal – The Medicines Company), an IV P2Y12 platelet inhibitor, as an adjunct to percutaneous coronary intervention (PCI) in patients who have not been pretreated with a…

Med Lett Drugs Ther. 2015 Oct 26; 57(1480):145-6
The FDA has approved cangrelor ( Kengreal – The Medicines Company), an IV P2Y12 platelet inhibitor, as an adjunct to percutaneous coronary intervention (PCI) in patients who have not been pretreated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Issue 1454 · October 27, 2014
Antithrombotic Drugs

Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention…

Med Lett Drugs Ther. 2014 Oct 27; 56(1454):103-8
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Issue 1451 · September 15, 2014
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events

The FDA has approved vorapaxar ( Zontivity – Merck), an oral protease-activated receptor-1 (PAR-1) antagonist, for use with aspirin and/or clopidogrel to reduce the risk of thrombotic cardiovascular events…

Med Lett Drugs Ther. 2014 Sep 15; 56(1451):85-6
The FDA has approved vorapaxar ( Zontivity – Merck), an oral protease-activated receptor-1 (PAR-1) antagonist, for use with aspirin and/or clopidogrel to reduce the risk of thrombotic cardiovascular events in patients with peripheral arterial disease or a history of myocardial infarction (MI). It is the first PAR-1 antagonist to be approved by the FDA.
Issue 110 · October 1, 2011
Antithrombotic Drugs

Arterial thrombi are composed mainly of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but…

Treat Guidel Med Lett. 2011 Oct; 9(110):61-6
Arterial thrombi are composed mainly of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but anticoagulants are also effective, and their effects can add to those of antiplatelet drugs. Venous thrombi are composed mainly of fibrin and trapped red blood cells, with relatively few platelets. Anticoagulants are the agents of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Issue 1372 · September 5, 2011
Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?

The FDA has approved ticagrelor ( Brilinta – AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary…

Med Lett Drugs Ther. 2011 Sep 5; 53(1372):69-70
The FDA has approved ticagrelor ( Brilinta – AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. Clopidogrel is expected to become available generically in the US within the next few months.